Dr. Daniel Pollyea has received degrees from the University of Chicago Pritzker School of Medicine and Stanford University. He served as Chief Medical Resident at Cook County Hospital in Chicago. He has been the Principal Investigator for multiple early-phase clinical trials and been involved in the clinical development and approval of four drugs for acute myeloid leukemia (AML). He has published over 100 peer-reviewed papers, spoken to audiences around the world about this work, and is currently the Chair of the National Comprehensive Cancer Network (NCCN) Guidelines Committee on AML. His work involves developing ways to target leukemia stem cells in patients with AML and myelodysplastic syndrome (MDS). Eradication can result in deep and durable remissions, or even cures. His team’s efforts have involved identifying vulnerabilities in the ways that leukemia stem cells process energy. These weaknesses can be specifically exploited with novel drug therapies, and Dr. Pollyea is focused on developing and running clinical trials that use these agents to target these weaknesses.